Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Joint Metastasis Research Society-AACR Conference on Metastasis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dahia, P. L.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dahia, P. L.M.
[Cancer Research 65, 9651-9658, November 1, 2005]
© 2005 American Association for Cancer Research


Molecular Biology, Pathobiology and Genetics

Novel Pheochromocytoma Susceptibility Loci Identified by Integrative Genomics

Patricia L.M. Dahia1, Ke Hao3, John Rogus4, Christian Colin1,6, Miguel A.G. Pujana7, Ken Ross8, Danielle Magoffin1, Neil Aronin9, Alberto Cascon10, César Y. Hayashida5, Cheng Li2, Sérgio P.A. Toledo5, Charles D. Stiles1 and for the Familial Pheochromocytoma Consortium

Departments of 1 Cancer Biology and 2 Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School; 3 Department of Biostatistics, Harvard School of Public Health, Research Division, Joslin Diabetes Center, Boston, Massachusetts; 4 Interleukin Genetics, Waltham, Massachusetts; Schools of 5 Medicine and 6 Chemistry, University of São Paulo, São Paulo, São Paulo, Brazil; 7 Translational Research Laboratory, Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain; 8 Broad Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts; 9 Division of Endocrinology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts; and 10 Molecular Pathology Program, National Center for Oncological Investigation, Madrid, Spain

Requests for reprints: Patricia L.M. Dahia, Departments of Medicine and Cellular and Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Drive, Room 5053-R3, MC 7880, San Antonio, TX 78229-3900. Phone: 210-567-4866; Fax: 210-567-1956; E-mail: dahia{at}uthscsa.edu.

Pheochromocytomas are catecholamine-secreting tumors that result from mutations of at least six different genes as components of distinct autosomal dominant disorders. However, there remain familial occurrences of pheochromocytoma without a known genetic defect. We describe here a familial pheochromocytoma syndrome consistent with digenic inheritance identified through a combination of global genomics strategies. Multipoint parametric linkage analysis revealed identical LOD scores of 2.97 for chromosome 2cen and 16p13 loci. A two-locus parametric linkage analysis produced maximum LOD score of 5.16 under a double recessive multiplicative model, suggesting that both loci are required to develop the disease. Allele-specific loss of heterozygosity (LOH) was detected only at the chromosome 2 locus in all tumors from this family, consistent with a tumor suppressor gene. Four additional pheochromocytomas with a similar genetic pattern were identified through transcription profiling and helped refine the chromosome 2 locus. High-density LOH mapping with single nucleotide polymorphism–based array identified a total of 18 of 62 pheochromocytomas with LOH within the chromosome 2 region, which further narrowed down the locus to <2 cM. This finding provides evidence for two novel susceptibility loci for pheochromocytoma and adds a recessive digenic trait to the increasingly broad genetic heterogeneity of these tumors. Similarly, complex traits may also be involved in other familial cancer syndromes.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
B. Bausch, A.-C. Koschker, M. Fassnacht, J. Stoevesandt, M. M. Hoffmann, C. Eng, B. Allolio, and H. P. H. Neumann
Comprehensive Mutation Scanning of NF1 in Apparently Sporadic Cases of Pheochromocytoma
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3478 - 3481.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
G. OPOCHER, F. SCHIAVI, M. IACOBONE, A. TONIATO, S. SATTAROVA, Z. ERLIC, M. MARTELLA, C. MIAN, I. MERANTE BOSCHIN, L. ZAMBONIN, et al.
Familial nonsyndromic pheochromocytoma.
Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 149 - 155.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
P. L.M DAHIA and FOR THE FAMILIAL PHEOCHROMOCYTOMA CONSORTIUM
Transcription Association of VHL and SDH Mutations Link Hypoxia and Oxidoreductase Signals in Pheochromocytomas.
Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 208 - 220.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2005 by the American Association for Cancer Research.